Your browser doesn't support javascript.
loading
Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer.
Virassamy, Balaji; Caramia, Franco; Savas, Peter; Sant, Sneha; Wang, Jianan; Christo, Susan N; Byrne, Ann; Clarke, Kylie; Brown, Emmaline; Teo, Zhi Ling; von Scheidt, Bianca; Freestone, David; Gandolfo, Luke C; Weber, Karsten; Teply-Szymanski, Julia; Li, Ran; Luen, Stephen J; Denkert, Carsten; Loibl, Sibylle; Lucas, Olivia; Swanton, Charles; Speed, Terence P; Darcy, Phillip K; Neeson, Paul J; Mackay, Laura K; Loi, Sherene.
Afiliação
  • Virassamy B; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Caramia F; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Savas P; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; The Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Melbourne, VIC, Australia.
  • Sant S; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; The Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Melbourne, VIC, Australia.
  • Wang J; Bioinformatics Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia; Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia.
  • Christo SN; Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia; Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Byrne A; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Clarke K; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Brown E; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Teo ZL; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; The Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Melbourne, VIC, Australia.
  • von Scheidt B; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Freestone D; Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Gandolfo LC; Bioinformatics Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia; Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Weber K; German Breast Cancer Group, GBG-Forschungs GmbH, Neu-Isenburg, Germany.
  • Teply-Szymanski J; German Breast Cancer Group, GBG-Forschungs GmbH, Neu-Isenburg, Germany; Department of Pathology, University Marburg-Giessen, Campus Marburg, Germany.
  • Li R; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Luen SJ; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; The Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Melbourne, VIC, Australia.
  • Denkert C; German Breast Cancer Group, GBG-Forschungs GmbH, Neu-Isenburg, Germany; Department of Pathology, University Marburg-Giessen, Campus Marburg, Germany.
  • Loibl S; German Breast Cancer Group, GBG-Forschungs GmbH, Neu-Isenburg, Germany.
  • Lucas O; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK; Computational Cancer Genomics Research Group, University College London Cancer Institute, London,
  • Swanton C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
  • Speed TP; Bioinformatics Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia; School of Mathematics and Statistics, University of Melbourne, Melbourne, VIC, Australia.
  • Darcy PK; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; The Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Melbourne, VIC, Australia. Electronic address: phil.darcy@petermac.org.
  • Neeson PJ; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; The Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Melbourne, VIC, Australia. Electronic address: paul.neeson@petermac.org.
  • Mackay LK; Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia; Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia. Electronic address: lkmackay@unimelb.edu.au.
  • Loi S; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; The Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Melbourne, VIC, Australia. Electronic address: sherene.loi@petermac.org.
Cancer Cell ; 41(3): 585-601.e8, 2023 03 13.
Article em En | MEDLINE | ID: mdl-36827978
ABSTRACT
CD8+ tumor-infiltrating lymphocytes with a tissue-resident memory T (TRM) cell phenotype are associated with favorable prognosis in patients with triple-negative breast cancer (TNBC). However, the relative contribution of CD8+ TRM cells to anti-tumor immunity and immune checkpoint blockade efficacy in breast cancer remains unknown. Here, we show that intratumoral CD8+ T cells in murine mammary tumors transcriptionally resemble those from TNBC patients. Phenotypic and transcriptional studies established two intratumoral sub-populations one more enriched in markers of terminal exhaustion (TEX-like) and the other with a bona fide resident phenotype (TRM-like). Treatment with anti-PD-1 and anti-CTLA-4 therapy resulted in expansion of these intratumoral populations, with the TRM-like subset displaying significantly enhanced cytotoxic capacity. TRM-like CD8+ T cells could also provide local immune protection against tumor rechallenge and a TRM gene signature extracted from tumor-free tissue was significantly associated with improved clinical outcomes in TNBC patients treated with checkpoint inhibitors.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article